KYORIN Pharmaceutical Co.,Ltd. [4569.T]
TOKYO, May 12 (Pulse News Wire) – Kyorin Pharmaceutical CO.,LTD. (4569.T) reported revenue of ¥1.263 trillion for the quarter ended March 2026, slightly below its previous estimate of ¥1.270 trillion.
Operating profit came in at ¥40.00 billion compared to the estimated ¥63 billion. Key drivers included lower sales of certain proprietary drugs such as Lasbic and Mukodain, offset by growth in domestic generics. Looking ahead, the company forecasts revenue of ¥1.218 trillion for the fiscal year ending March 2027, citing anticipated growth in flagship products Beovar and Desareks but also noting expected declines due to increased competition from generics.
Research and development expenses are projected to decrease amid reduced contract payments for new drug introductions. In addition, KYORIN highlighted strong performance from its key product Beovar, which saw sales increase by 23.5% to ¥92.30 billion, driven by ongoing patient education initiatives and expanded adoption in primary care settings. Despite challenges, the company remains optimistic about long-term prospects in key therapeutic areas.
🟡 Confidence: Standard AI-translated content.